Bipolar Disorder Market 2018 Global Analysis, Opportunities and Forecast to 2025

This report focuses on the global Bipolar Disorder status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Bipolar Disorder development in United States, Europe and China.

Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. There are four basic types of bipolar disorder; all of them involve clear changes in mood, energy, and activity levels.
People suffering with bipolar disorder have intense emotional states that occur in distinct periods called mood episodes. Mood episode is characterized by drastic changes in person’s usual mood and their behavior. Mood episode is mainly classified into two main types: manic episodes and depressive episodes. An overexcited or joyful state is called a manic episode and an extremely hopeless or sad state is called a depressive episode. Sometimes, a mood episode includes symptoms of both depression and mania, known as mixed state. These mood episodes hamper school and job performance.
In 2017, the global Bipolar Disorder market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

Request a Sample Report @  https://www.wiseguyreports.com/sample-request/3351458-global-bipolar-disorder-market-size-status-and-forecast-2018-2025

The key players covered in this study
Glaxo SmithKline (GSK)
Pfizer
Janssen Pharmaceuticals
Eli Lilly
Allergan
Novartis
AbbVie
Otsuka
AstraZeneca

Market segment by Type, the product can be split into
Selective Serotonin Reuptake Inhibitor
Serotonin Norepinephrine Reuptake Inhibitors
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Benzodiazepines
Beta Blockers

Market segment by Application, split into
Mood Stabilizers
Anticonvulsants
Antipsychotic drugs
Antidepressant drugs
Antianxiety drugs

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Bipolar Disorder status, future forecast, growth opportunity, key market and key players.
To present the Bipolar Disorder development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Bipolar Disorder Market Size Growth Rate by Type (2013-2025)
1.4.2 Selective Serotonin Reuptake Inhibitor
1.4.3 Serotonin Norepinephrine Reuptake Inhibitors
1.4.4 Tricyclic Antidepressants
1.4.5 Monoamine Oxidase Inhibitors
1.4.6 Benzodiazepines
1.4.7 Beta Blockers
1.5 Market by Application
1.5.1 Global Bipolar Disorder Market Share by Application (2013-2025)
1.5.2 Mood Stabilizers
1.5.3 Anticonvulsants
1.5.4 Antipsychotic drugs
1.5.5 Antidepressant drugs
1.5.6 Antianxiety drugs
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Bipolar Disorder Market Size
2.2 Bipolar Disorder Growth Trends by Regions
2.2.1 Bipolar Disorder Market Size by Regions (2013-2025)
2.2.2 Bipolar Disorder Market Share by Regions (2013-2018)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Bipolar Disorder Market Size by Manufacturers
3.1.1 Global Bipolar Disorder Revenue by Manufacturers (2013-2018)
3.1.2 Global Bipolar Disorder Revenue Market Share by Manufacturers (2013-2018)
3.1.3 Global Bipolar Disorder Market Concentration Ratio (CR5 and HHI)
3.2 Bipolar Disorder Key Players Head office and Area Served
3.3 Key Players Bipolar Disorder Product/Solution/Service
3.4 Date of Enter into Bipolar Disorder Market
3.5 Mergers & Acquisitions, Expansion Plans

..............

12 International Players Profiles
12.1 Glaxo SmithKline (GSK)
12.1.1 Glaxo SmithKline (GSK) Company Details
12.1.2 Company Description and Business Overview
12.1.3 Bipolar Disorder Introduction
12.1.4 Glaxo SmithKline (GSK) Revenue in Bipolar Disorder Business (2013-2018)
12.1.5 Glaxo SmithKline (GSK) Recent Development
12.2 Pfizer
12.2.1 Pfizer Company Details
12.2.2 Company Description and Business Overview
12.2.3 Bipolar Disorder Introduction
12.2.4 Pfizer Revenue in Bipolar Disorder Business (2013-2018)
12.2.5 Pfizer Recent Development
12.3 Janssen Pharmaceuticals
12.3.1 Janssen Pharmaceuticals Company Details
12.3.2 Company Description and Business Overview
12.3.3 Bipolar Disorder Introduction
12.3.4 Janssen Pharmaceuticals Revenue in Bipolar Disorder Business (2013-2018)
12.3.5 Janssen Pharmaceuticals Recent Development
12.4 Eli Lilly
12.4.1 Eli Lilly Company Details
12.4.2 Company Description and Business Overview
12.4.3 Bipolar Disorder Introduction
12.4.4 Eli Lilly Revenue in Bipolar Disorder Business (2013-2018)
12.4.5 Eli Lilly Recent Development
12.5 Allergan
12.5.1 Allergan Company Details
12.5.2 Company Description and Business Overview
12.5.3 Bipolar Disorder Introduction
12.5.4 Allergan Revenue in Bipolar Disorder Business (2013-2018)
12.5.5 Allergan Recent Development
12.6 Novartis
12.6.1 Novartis Company Details
12.6.2 Company Description and Business Overview
12.6.3 Bipolar Disorder Introduction
12.6.4 Novartis Revenue in Bipolar Disorder Business (2013-2018)
12.6.5 Novartis Recent Development
12.7 AbbVie
12.7.1 AbbVie Company Details
12.7.2 Company Description and Business Overview
12.7.3 Bipolar Disorder Introduction
12.7.4 AbbVie Revenue in Bipolar Disorder Business (2013-2018)
12.7.5 AbbVie Recent Development
12.8 Otsuka
12.8.1 Otsuka Company Details
12.8.2 Company Description and Business Overview
12.8.3 Bipolar Disorder Introduction
12.8.4 Otsuka Revenue in Bipolar Disorder Business (2013-2018)
12.8.5 Otsuka Recent Development
12.9 AstraZeneca
12.9.1 AstraZeneca Company Details
12.9.2 Company Description and Business Overview
12.9.3 Bipolar Disorder Introduction
12.9.4 AstraZeneca Revenue in Bipolar Disorder Business (2013-2018)
12.9.5 AstraZeneca Recent Development

13 Market Forecast 2018-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2018-2025)
13.10 Market Size Forecast by Application (2018-2025)

……Continued

Access Complete Report @ https://www.wiseguyreports.com/reports/3351458-global-bipolar-disorder-market-size-status-and-forecast-2018-2025

Contact Us:

Norah Trent

Partner Relations & Marketing Manager

Sales@Wiseguyreports.Com                                                                               

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)